Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by canadapieton Apr 04, 2016 10:24am

88 Views

Post# 24727354

RE:RE:Belly Fat

SPCEO1 ,

you were always telling that TH should be at 2 and could be worth 5-6 CAD on Egrifta ! Now you are saying to look for the new product and forget the old one ! It isn't even approved ,so to me it looks a little speculative for that one . Are you still sticking with your prognosis on Egrifta so the price of TH could reach lets say 2 cad on Egrifta alone within 12 months ??

Thx

Bullboard Posts

The top 10 Canadian medical stocks